A Novel EPO Receptor Agonist Improves Glucose Tolerance via Glucose Uptake in Skeletal Muscle in a Mouse Model of Diabetes
Figure 6
Hyperinsulinemic-euglycemic clamp following a single dose of CNTO 530. (a) The glucose infusion rate in DIO mice treated IV with CNTO 530 (0.3 mg/kg) or PBS measured fourteen days after drug administration (). (b) The glucose uptake into peripheral tissues in DIO mice treated IV with CNTO 530 (0.3 mg/kg) or PBS measured fourteen days after drug administration. A nonhydrolyzable, radiolabeled glucose molecule was dosed as a bolus to the animals 40 minutes before the end of the clamp. The amount of glucose taken up into the skeletal muscle (c), the heart (d), the visceral fat (e), and the epididymal fat (f). *indicates a P value < .05. ***indicates a P value < .005.
